Noninvasive Detection of AR-FL/AR-V7 as a Predictive Biomarker for Therapeutic Resistance in Men with Metastatic Castration-Resistant Prostate Cancer
Technical Report,30 Sep 2015,29 Sep 2016
University of Washington Seattle United States
Pagination or Media Count:
Subject Primary and acquired resistance to abiraterone and enzalutamide represent critical problems in contemporary prostate cancer clinical care, and development of predictive biomarkers of response and resistance to abiraterone and enzalutamide remains an urgent and unmet need. Purpose The overall goal of this Biomarker Development Award proposal is to enable near-term clinical use of a noninvasive test for prediction and assessment of response to abiraterone and enzalutamide in men with metastatic prostate cancer. Scope A predictive biomarker of therapeutic resistance to the two agents is likely to generate therapeutic benefit to men with mCRPC by facilitating earlier treatment decisions regarding the type and sequence of therapy, given the availability of other FDA-approved therapies and experimental therapies. This predictive marker will also drive the development of novel therapeutic approaches designed to overcome resistance to abiraterone and enzalutamide.
- Medicine and Medical Research